Please enable JavaScript in your browser. 

Important Announcement


DrugPortal is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip to main content
Drug Information Portal National Library of Medicine

Category Names, Results, and Descriptions


Male Fertility Agents, Synthetic (0) see Fertility Agents, Male

Mast Cell Stabilizers (2)

Matrix Metalloproteinase Inhibitors (17) • Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES. MeSH

Membrane Transport Modulators (299) • Agents that affect ION PUMPS; ION CHANNELS; ABC TRANSPORTERS; and other MEMBRANE TRANSPORT PROTEINS. MeSH

Menstruation-Inducing Agents (2) • Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhea is a secondary result. (From Dorland, 27th ed) MeSH

Metabolic Side Effects of Drugs and Substances (58)

Metal Antagonists (0) see Chelating Agents

Metal Chelating Agents (0) see Chelating Agents

Microbicides (0) see Anti-Infective Agents

Microbicides, Topical (0) see Anti-Infective Agents, Local

Micronutrients (93) • Essential dietary elements or organic compounds that are required in only small quantities for normal physiologic processes to occur. MeSH

Mineralocorticoid Effect (0) see Mineralocorticoids

Mineralocorticoid Receptor Antagonists (7) • Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE. MeSH

Mineralocorticoid Synthesis Inhibitors (0) see Steroid Synthesis Inhibitors

Mineralocorticoids (2) • A group of CORTICOSTEROIDS primarily associated with water and electrolyte balance. This is accomplished through the effect on ION TRANSPORT in renal tubules, resulting in retention of sodium and loss of potassium. Mineralocorticoid secretion is itself regulated by PLASMA VOLUME, serum potassium, and ANGIOTENSIN II. MeSH

Miotic Effect (0) see Miotics

Miotics (8) • Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. MeSH

Mitogens (10) • Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) MeSH

Mitosis Modulators (31)

Molecular Probes (7)

Molluscacides (6) • Agents destructive to snails and other mollusks. MeSH

Monoamine Oxidase Inhibitors (37) • A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MeSH

Morning-After Pill (0) see Contraceptives, Postcoital

Mouthwashes (7) • Solutions for rinsing the mouth, possessing cleansing, germicidal, or palliative properties. (From Boucher's Clinical Dental Terminology, 4th ed) MeSH

MTOR Inhibitors (1)

Mucolytic Agents (0) see Expectorants

Muscarinic Agents (0) see Cholinergic Agents

Muscarinic Agonists (11) • Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. MeSH

Muscarinic Antagonists (50) • Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. MeSH

Muscarinic Effect (0) see Cholinergic Agents

Muscle Relaxants, Central (28) • A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) MeSH

Mutagens (118) • Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. MeSH

Mydriatic Effect (0) see Mydriatics

Mydriatics (16) • Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. MeSH

Myeloablative Agonists (5) • Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION. MeSH

Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
HHS Vulnerability Disclosure
Drug Information Portal Mobile Site
Last updated: Nov 2022